Trial Profile
Phase II Evaluation of Real-Time, Pharmacokinetically Guided Everolimus in Patients With Hormone Receptor Positive Breast Cancer, Pancreatic Neuroendocrine Tumors (PNET), and Renal Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Neuroendocrine tumours; Pancreatic cancer; Renal cell carcinoma
- Focus Adverse reactions
- 12 Jan 2016 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
- 04 Nov 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 28 Oct 2014 New trial record